Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

25 Nov 2022

Abstract excerpt

BACKGROUND: Fragile X syndrome (FXS) is associated with dysregulated endocannabinoid signaling and may therefore respond to cannabidiol therapy. DESIGN: CONNECT-FX was a double-blind, randomized phase 3 trial assessing efficacy and safety of ZYN002, transdermal cannabidiol gel, for the treatment of behavioral symptoms in children and adolescents with FXS. METHODS: ) SA subscale in a full cohort of patients with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Attention Deficit Hyperactivity Disorder
Share to Cannabis and Cannabinoid Research
Share to Genetics and Neurodevelopmental Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36434514
DOI: 10.1186/s11689-022-09466-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)PMID 36434514Read ↗

Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatmentSemantic proximity Read ↗

Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence.Semantic proximity Read ↗

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment.Semantic proximity Read ↗

Fragile X syndrome: A review of clinical managementSemantic proximity Read ↗

The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome.Semantic proximity Read ↗

Fragile X syndrome: clinical presentation, pathology and treatment.Semantic proximity Read ↗

Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry PerspectiveSemantic proximity Read ↗

Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.Semantic proximity Read ↗

Fragile X syndrome: a psychiatric perspective.Semantic proximity Read ↗

Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study.Semantic proximity Read ↗

Clinical Validation of Fragile X Syndrome Screening by DNA Methylation Array.Semantic proximity Read ↗

Mental Illnesses-Associated Fxr1 and Its Negative Regulator Gsk3β Are Modulators of Anxiety and Glutamatergic NeurotransmissionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.